M 1641 \$
PATENT

Attorney Docket No. 064727.0105

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Allan William CRIPPS et al.

Application Number:

Filed: July 22, 19

For:

ANTIGEN

Commissioner for Patents

United States Patent and Trademark Office

09/359,4261

JUL 1 9 2000

Washington, D.C. 20231

Group Art Unit: 1641

Examiner: S. DEVI

RECEIVED

JUL 26 2021

TECHCENTE 600/2900

^{ДЦІЎ} О<u>Т</u> 20**00**

PETITION FOR EXTENSION OF TIME, SUBMISSION OF SEQUENCE LISTING AND RESPONSE TO RESTRICTION REQUIREMENT

Sir:

Applicants respectfully request a one-month extension of time under 37 C.F.R. §1.136(a) for responding to the Restriction Requirement mailed May 19, 2000 in the above-identified application. Accordingly, it is respectfully requested that the time for response be extended up to and including **July 19, 2000**.

Our check in the amount of \$110.00 is attached to cover the one-month extension fee. In the event any variance exists between the amount of the extension fee enclosed and the Patent Office charges, please charge or credit any difference to the undersigned's Deposit Account No. 02-0375.

SUBMISSION OF SEQUENCE LISTING

In response to the Notice to Comply with Requirements mailed May 19, 2000, Applicants respectfully submit the enclosed Sequence Listing.

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Requirement for Restriction, Applicants elect Group I, claims 1-, 18-20 and 21-27, without traverse.

07/21/2000 BHABTEW 00000033 09359426

01 FC:115

110.00 OP

DC01:268262.1

Application-10: 09/359,426

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

OIPE	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	
JUL 1 9 2000	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
A VANDEMA	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	
[4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
ĺ	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	ţ
•	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
	7. Other:	
	Applicant Must Provide:	
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its en into the specification.	try
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
	For questions regarding compliance to these requirements, please contact:	
	For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support (SIRA)	
	Technical Assistance703-287-0200	
	To Purchase PatentIn Software703-306-2600	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE